Mitoxantrone plus cytarabine versus daunorubicin plus cytarabine as induction therapy for previously untreated adult patients with acute myeloid leukemia

Pakistan Journal of Medical Sciences

Volumn 23, Issue 6, 2007, Pages 909-912

  Nikanfar, Alireza ^a   Asvadi, Iraj ^a   Vaez, Jalil ^a  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

AML; Cytarabine; Mitoxantrone

Indexed keywords

CYTARABINE; DAUNORUBICIN; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; MALE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TREATMENT DURATION;

EID: 36949024965     PISSN: 1682024X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. th ed ) (vol.1), Lichtman MA, Beutler E, Kipps TJ, (Eds), In: McGraw-Hill Medical publishing Division, New York. 2006;1183-211.
2. Wiernik PH, Banks PL, Case DC Jr, Arlin ZA, Periman PO, Todd MB, et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 1992;79(2):313-9.
3. th ed ), Greer JP, Foerster JN, Lukens J, Rodgers GM, Paraskevas F, Glader B (Eds), Lippincott Williams & Wilkins Philadelphia 2004;2097-142.
4. Anderson J, Kopecky K, Willman C, Head D, O'Donnel M, Luthardt F, et al. Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with miotozanfrome and etoposide compared to cytarabine and daunorubicin. Blood 2002;100:3869-76.
5. Yin JAL, Johnson PRE, Daview JM, Flanagan NG, Grost DW, Lewis MJ. Mitoxantrone and cytosine arabinoside as first-line therapy in elderly patients with acute myeloid leukemia. Br J Haematol 1991;79:415-20.
6. Dalley CD, Lillington DL, Bradburn M, Carter M, Amess JA, Rohatiner AZ, et al. Acute myelogenous leukemia in older patients at st Bartholom ew's Hospital: outcome with mitoxantrone and cytarabine. Hematol J 2002;3(5):237-43.
7. Paciucci PA, Cuttner J, Holland JF. Sequential intermediate dose cytosine arabinoside and mitoxantrone for patients with relapsed and refractory acute myelocitic leukemia. Am J Hematol 1990;35:22-5.
8. Thomas X, Archimbaud E. Mitoxantrone in the treatment of acute myelogenous leukemia: a review. Hematol Cell Ther 1997;39(4):63-74.
9. Sternberg DW, Aird W, Neuberg D, Thompson L, MacNevill K, Amrein P, et al. In: Teatment of patients with recurrent and primary refractory acute myelogenous leukemia using mitoxantrone and intermediate-dose cytarabine. Cancer 2000;88(9):2037-41.
10. MaCallum PK, Rohatiner AZ, Davis CL, Whelan JS, Oza AM, Lim J, et al. Mitoxantrone and cytosine arabinoside as treatment for acute myeloblastic leukemia in older patients. Ann Hematol 1995;71:35-9.
11. Lowenberg B, Suciu S, Archimbaud E, Haak H, Stryckmans P, de cataldo R, et al. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy -the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly. J Clin Oncol 1998;16(3):872-8.
12. Paciucci PA, Cuttner J, Gottlieb A, Davis RB, Martelo O, Holland JE. Sequential mitoxantrone daunorubicin and cytosine arabinoside for patients with newly diagnosed acute myelocytic leukemia. Am J Hematol 1997;56:214-8.
13. Al Bahar S, Pandita R, Bavishi K, Savani B. Sequential standard dose mitoxantrone and cytosine arabinoside for newly diagnosed adult acute myeloblastic leukemia. Neoplasma 1999;46:61-5.
14. Koc Y, Oyan B, Kars A, Tekuzman G, Canpinar H, Kansu E. A randomized trial of continuous infusion versus bolus mitoxantrone in combination with cytarabine in newly diagnosed patients with acute myeloblastic leukemia. Hematol Oncol 2004;22:43-53.
15. Arlin ZA, Case DC Jr, Moor J, Wiernik P, Feldaman E, Saletan S, et al. Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia(ANLL). Leukemia, 1990;4:177-83.
16. Pavlovsky S, Gonzalez Llaren J, Garsia Martinez MA, Sobrevilla P, Eppinger-Helft M, Marin A, et al. A randomized study of mitoxantrone plus cytarabine versus daunomycin plus cytarabine in the treatment of previously untreated adult patients with acute non lymphocytic leukemia. Ann Hematol 1994;69:11-5.